

## Special Issue

# Immunotherapeutic Strategies in Cancer and Chronic Infection

### Message from the Guest Editors

Despite enormous therapeutic advancements, cancer and infectious diseases are still major causes of morbidity and mortality. Immunotherapies are strategies that involve modulating the immune system in precise ways, prompting the body's own immune system to fight diseases more effectively. Several different categories of immunotherapies exist, including those based on monoclonal antibodies, cell therapies, vaccines, oncolytic viruses, checkpoint inhibitors and cytokines. Novel and innovative therapeutic strategies are necessary to overcome the challenges typically faced in cancer and existing infectious diseases; indeed, despite encouraging results, these therapies are often endowed with toxicity or lack of adequate efficacy. In this Special Issue, original research articles and reviews highlighting the role of different forms of immunotherapy on treatment of both cancer and chronic infections, covering both basic research and clinical aspects, are welcome. We look forward to receiving your contributions.

---

### Guest Editors

Dr. Gaia Codolo

Dr. Barbara Frossi

Dr. Teresa Zelante

---

### Deadline for manuscript submissions

closed (30 April 2023)



## Pharmaceutics

---

an Open Access Journal  
by MDPI

---

Impact Factor 5.5  
CiteScore 10.0  
Indexed in PubMed



[mdpi.com/si/137908](https://mdpi.com/si/137908)

*Pharmaceutics*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[pharmaceutics@mdpi.com](mailto:pharmaceutics@mdpi.com)

[mdpi.com/journal/  
pharmaceutics](https://mdpi.com/journal/pharmaceutics)





# Pharmaceutics

---

an Open Access Journal  
by MDPI

---

Impact Factor 5.5  
CiteScore 10.0  
Indexed in PubMed



[mdpi.com/journal/  
pharmaceutics](https://mdpi.com/journal/pharmaceutics)



## About the Journal

### Message from the Editor-in-Chief

*Pharmaceutics* (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

---

### Editor-in-Chief

Prof. Dr. Patrick J. Sinko  
Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, William Levine Hall, Room 225C, 160 Frelinghuysen Road, Piscataway, NJ 08854-8020, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).